Literature DB >> 30312420

Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?

Joseph A Sparano1, N Lynn Henry2.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30312420      PMCID： PMC6934435          DOI： 10.1093/jnci/djy153

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  29 in total

1.  Ca 15-3 in the follow-up of localised breast cancer: a prospective study.

Authors:  R Kokko; K Holli; M Hakama
Journal:  Eur J Cancer       Date:  2002-06       Impact factor: 9.162

2.  Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease.

Authors:  D W Chan; R A Beveridge; H Muss; H A Fritsche; G Hortobagyi; R Theriault; D Kiang; B J Kennedy; M Evelegh
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

3.  Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.

Authors:  Elisabeth Trapp; Wolfgang Janni; Christian Schindlbeck; Julia Jückstock; Ulrich Andergassen; Amelie de Gregorio; Marianna Alunni-Fabbroni; Marie Tzschaschel; Arkadius Polasik; Julian G Koch; Thomas W P Friedl; Peter A Fasching; Lothar Haeberle; Tanja Fehm; Andreas Schneeweiss; Matthias W Beckmann; Klaus Pantel; Volkmar Mueller; Brigitte Rack; Christoph Scholz
Journal:  J Natl Cancer Inst       Date:  2019-04-01       Impact factor: 13.506

4.  CDK4/6 Inhibitors in Combination With Hormone Therapy for HR+/HER2- Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Yunfu Deng; Guangzhi Ma; Wen Li; Ting Wang; Yaqin Zhao; Qiang Wu
Journal:  Clin Breast Cancer       Date:  2018-05-04       Impact factor: 3.225

5.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Authors:  Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

6.  Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

Authors:  Rita Nanda; Laura Q M Chow; E Claire Dees; Raanan Berger; Shilpa Gupta; Ravit Geva; Lajos Pusztai; Kumudu Pathiraja; Gursel Aktan; Jonathan D Cheng; Vassiliki Karantza; Laurence Buisseret
Journal:  J Clin Oncol       Date:  2016-05-02       Impact factor: 44.544

7.  Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients.

Authors:  R Molina; G Zanón; X Filella; F Moreno; J Jo; M Daniels; M L Latre; N Giménez; J Pahisa; M Velasco
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

Review 8.  American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.

Authors:  Carolyn D Runowicz; Corinne R Leach; N Lynn Henry; Karen S Henry; Heather T Mackey; Rebecca L Cowens-Alvarado; Rachel S Cannady; Mandi L Pratt-Chapman; Stephen B Edge; Linda A Jacobs; Arti Hurria; Lawrence B Marks; Samuel J LaMonte; Ellen Warner; Gary H Lyman; Patricia A Ganz
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

9.  Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.

Authors:  Mitch Dowsett; Ivana Sestak; Meredith M Regan; Andrew Dodson; Giuseppe Viale; Beat Thürlimann; Marco Colleoni; Jack Cuzick
Journal:  J Clin Oncol       Date:  2018-04-20       Impact factor: 44.544

Review 10.  Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.

Authors:  François-Clément Bidard; Tanja Fehm; Michail Ignatiadis; Jeffrey B Smerage; Catherine Alix-Panabières; Wolfgang Janni; Carlo Messina; Costanza Paoletti; Volkmar Müller; Daniel F Hayes; Martine Piccart; Jean-Yves Pierga
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264
View more
  3 in total

1.  RE: Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.

Authors:  Serenai Di Cosimo; Valter Torri; Luca Porcu
Journal:  J Natl Cancer Inst       Date:  2019-11-01       Impact factor: 13.506

2.  Response to Di Cosimo, Torri, and Porcu.

Authors:  Elisabeth Trapp; Wolfgang Janni; Christian Schindlbeck; Julia Jückstock; Ulrich Andergassen; Amelie deGregorio; Marianna Alunni-Fabbroni; Marie Tzschaschel; Arkadius Polasik; Julian G Koch; Thomas W P Friedl; Peter A Fasching; Lothar Haeberle; Tanja Fehm; Andreas Schneeweiss; Matthias W Beckmann; Klaus Pantel; Volkmar Mueller; Brigitte Rack; Christoph Scholz
Journal:  J Natl Cancer Inst       Date:  2019-11-01       Impact factor: 13.506

3.  EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.

Authors:  Fanny Le Du; Takeo Fujii; Kumiko Kida; Darren W Davis; Minjeong Park; Diane D Liu; Weiguo Wu; Mariana Chavez-MacGregor; Carlos H Barcenas; Vicente Valero; Debu Tripathy; James M Reuben; Naoto T Ueno
Journal:  PLoS One       Date:  2020-03-26       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.